New test aims to predict which lung cancer patients will respond to immunotherapy

NCT ID NCT05478538

Ongoing Knowledge-focused Sponsor: Elephas Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 17 times

Summary

This study collects tumor tissue from 200 people with advanced non-small cell lung cancer to train a new diagnostic platform. The goal is to see if the platform can accurately predict how well a patient will respond to immunotherapy drugs. Participants provide tissue samples, and researchers compare the test results to actual treatment outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Baylor Scott & White Research Institute

Temple, Texas, 76508, United States
Gabrail Cancer Center

Canton, Ohio, 44718, United States
JPS Health Network

Fort Worth, Texas, 76104, United States
James M Stockman Cancer Institute

Frederick, Maryland, 21702, United States
New York Cancer & Blood Specialists

Shirley, New York, 11967, United States
UCLA Medical Center

Los Angeles, California, 90095, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER NSCLC (NON-SMALL CELL LUNG CANCER)